ItHome Hypertension J&J and Laurus Settle Patent Suit on Opsumit Hypertension Drug

J&J and Laurus Settle Patent Suit on Opsumit Hypertension Drug

Credits to the 👉🏾Source Link👉🏾 Olivia
Emergency Rooms See Fewer Heart Attacks, Strokes in Pandemic
IP Law News

Jan. 25, 2021, 3:34 PM

J&J’s Actelion unit had claimed that a generic version of pulmonary hypertension drug Opsumit jointly proposed by Laurus and closely held PharmaQ infringes a patent.

  • Laurus conceded the patent’s validity and that its copycat would infringe, and Laurus agreed to be blocked from making copies until the patent has expired “unless otherwise specifically authorized” by Actelion, according to consent judgment approved Friday in federal court in Wilmington, Delaware
    • Judgment mentions license agreement but provides no further details
  • Opsumit had U.S. sales of $729 million during the first nine months of 2020, up from $581 million during the same period…

Source Link

related posts

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: